The Human Trisome Project
HTP
Research to Develop the Human Trisome Project Biobank
2 other identifiers
observational
2,500
1 country
1
Brief Summary
The Human Trisome Project will significantly increase the speed of Down syndrome research and the understanding of associated medical conditions. Its biobank will provide de-identified samples to research.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2016
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2016
CompletedFirst Submitted
Initial submission to the registry
July 21, 2016
CompletedFirst Posted
Study publicly available on registry
August 11, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2036
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2036
October 24, 2025
October 1, 2025
20 years
July 21, 2016
October 22, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Number of Participants and Controls Enrolled in Biobank
Create biobank of blood cells and plasma, saliva, mouth swab, urine, stool, and induced pluripotent stem cells (iPSC) cells for use in approved research projects.
5 years
Secondary Outcomes (2)
Number of Clinical Records Available for Approved Research Purposes
5 years
Multidimensional Sample Characterization
5 years
Study Arms (2)
Those with trisomy 21
People aged 6 months to 89 years old who have some form of trisomy 21.
Controls
People aged 6 months to 89 years old who do not have trisomy 21. These persons can be related to someone with some form of trisomy 21 but do not have to be related.
Eligibility Criteria
Individuals with Down syndrome, individuals related to someone with Down syndrome or of the general population who do not have a relationship to Down syndrome.
You may qualify if:
- Anyone 6 months to 89 years old who:
- has Down syndrome (any type)
- does not have Down syndrome
You may not qualify if:
- Prisoners
- Wards of the state
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Colorado, Denverlead
- Linda Crnic Institute for Down Syndromecollaborator
- National Center for Advancing Translational Sciences (NCATS)collaborator
- GLOBAL Down Syndrome Foundationcollaborator
- Anna and John J. Sie Foundationcollaborator
Study Sites (1)
Linda Crnic Institute for Down Syndrome at the University of Colorado Denver
Denver, Colorado, 80045, United States
Related Publications (1)
Waugh KA, Araya P, Pandey A, Jordan KR, Smith KP, Granrath RE, Khanal S, Butcher ET, Estrada BE, Rachubinski AL, McWilliams JA, Minter R, Dimasi T, Colvin KL, Baturin D, Pham AT, Galbraith MD, Bartsch KW, Yeager ME, Porter CC, Sullivan KD, Hsieh EW, Espinosa JM. Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome. Cell Rep. 2019 Nov 12;29(7):1893-1908.e4. doi: 10.1016/j.celrep.2019.10.038.
PMID: 31722205DERIVED
Related Links
Biospecimen
blood, saliva, mouth swab, urine (optional), stool (optional)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Joaquin Espinosa, PhD
Linda Crnic Institute for Down Syndrome at the University of Colorado Denver
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 21, 2016
First Posted
August 11, 2016
Study Start
July 1, 2016
Primary Completion (Estimated)
July 1, 2036
Study Completion (Estimated)
July 1, 2036
Last Updated
October 24, 2025
Record last verified: 2025-10
Data Sharing
- IPD Sharing
- Will not share